Equities Analysts Set Expectations for ZVRA FY2029 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Analysts at Roth Capital issued their FY2029 earnings estimates for shares of Zevra Therapeutics in a research report issued to clients and investors on Sunday, February 9th. Roth Capital analyst J. Aschoff anticipates that the company will earn $2.26 per share for the year. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The business had revenue of $3.70 million during the quarter, compared to analyst estimates of $5.04 million. During the same period in the previous year, the company posted ($0.40) EPS.

A number of other equities research analysts have also recently issued reports on ZVRA. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Zevra Therapeutics in a research note on Wednesday, November 20th. Canaccord Genuity Group cut their target price on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Thursday, November 14th. Finally, Cantor Fitzgerald raised shares of Zevra Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 29th. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $21.57.

Zevra Therapeutics Price Performance

Shares of ZVRA opened at $7.53 on Tuesday. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. The stock’s 50 day moving average is $8.37 and its two-hundred day moving average is $8.01. Zevra Therapeutics has a 12 month low of $4.20 and a 12 month high of $9.76.

Hedge Funds Weigh In On Zevra Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. The Manufacturers Life Insurance Company lifted its stake in Zevra Therapeutics by 15.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock worth $91,000 after purchasing an additional 2,452 shares in the last quarter. Sanctuary Advisors LLC purchased a new position in Zevra Therapeutics during the second quarter worth approximately $474,000. SG Americas Securities LLC acquired a new position in Zevra Therapeutics during the third quarter worth $105,000. City State Bank boosted its stake in Zevra Therapeutics by 14.1% during the third quarter. City State Bank now owns 16,224 shares of the company’s stock worth $113,000 after buying an additional 2,000 shares during the last quarter. Finally, IFG Advisors LLC grew its holdings in Zevra Therapeutics by 41.2% in the 3rd quarter. IFG Advisors LLC now owns 26,400 shares of the company’s stock valued at $183,000 after buying an additional 7,700 shares in the last quarter. 35.03% of the stock is currently owned by institutional investors and hedge funds.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.